Trends and considerations in cell and gene therapy M&A, partnering and IP

Cell & Gene Therapy Insights 2022; 8(3), 493–497

DOI: 10.18609/cgti.2022.073

Published: 11 May 2022
Ewan Townsend

David McCall, Editor, Cell and Gene Therapy Insightsspeaks to Ewan Townsend, Partner, Arnold & Porter

Ewan Townsend’s practice at Arnold & Porter focusses on the commercial transactions involved in the development, exploitation and commercialization of medicinal products, representing many of the world’s most sophisticated biotechnology and pharmaceutical companies. His experience includes structuring, drafting and negotiating licence and collaboration agreements, manufacturing, distribution and supply agreements, material transfer agreements, clinical trial agreements, services agreements, co-promotion/co-development alliances, pharmacovigilance and quality agreements. Ewan also advises on the regulatory issues that frequently arise in the context of those transactions and throughout the medicinal product life cycle, particularly in relation to marketing authorizations, manufacturing, distribution, advertising, pricing and reimbursement.